GAMMA Investing LLC Purchases Shares of 270 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

GAMMA Investing LLC purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 270 shares of the biopharmaceutical company’s stock, valued at approximately $52,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Quent Capital LLC boosted its position in Alnylam Pharmaceuticals by 246.0% in the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 123 shares in the last quarter. Anchor Investment Management LLC acquired a new position in Alnylam Pharmaceuticals in the fourth quarter valued at about $38,000. Lindbrook Capital LLC boosted its position in Alnylam Pharmaceuticals by 37.2% in the fourth quarter. Lindbrook Capital LLC now owns 369 shares of the biopharmaceutical company’s stock valued at $71,000 after buying an additional 100 shares in the last quarter. Acadian Asset Management LLC boosted its position in Alnylam Pharmaceuticals by 52.4% in the third quarter. Acadian Asset Management LLC now owns 904 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 311 shares in the last quarter. Finally, Avitas Wealth Management LLC acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $204,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ALNY. Citigroup reduced their target price on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating on the stock in a research report on Friday, February 16th. Royal Bank of Canada reiterated an “outperform” rating and set a $235.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. Cantor Fitzgerald reiterated a “neutral” rating and set a $165.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. Wells Fargo & Company reduced their target price on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating on the stock in a research report on Friday, February 16th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $200.00 target price on shares of Alnylam Pharmaceuticals in a research report on Thursday. Seven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $215.88.

View Our Latest Analysis on Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY opened at $150.31 on Friday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $218.88. The company has a market capitalization of $18.93 billion, a PE ratio of -42.47 and a beta of 0.41. The company has a 50 day moving average price of $150.01 and a two-hundred day moving average price of $165.35.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Free Report) last issued its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, beating the consensus estimate of ($1.20) by $0.10. The firm had revenue of $439.72 million during the quarter, compared to the consensus estimate of $439.38 million. The firm’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same period in the previous year, the company posted ($1.68) EPS. On average, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -4.46 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

(Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Read More

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.